N-(2-Hydroxypropyl) methacrylamide

ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

Retrieved on: 
Wednesday, February 24, 2021
Biotechnology, General Health, Health, Oncology, Cancer treatments, Clinical medicine, Medicine, Immunology, ImmunoGen, Antineoplastic drugs, Antibody-drug conjugate, N-(2-Hydroxypropyl) methacrylamide

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference.
  • The presentation will be available on-demand on March 9, 2021 at 7:00 a.m.
  • A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients.

Biocompatible Materials Market to Reach US$ 347 Bn by 2030; COVID-19 Restrictions to Moderately Affect Growth Prospects in Near Term - Persistence Market Research

Retrieved on: 
Friday, January 22, 2021
Biomolecules, Acrylamides, Monomers, N-(2-Hydroxypropyl) methacrylamide, Biomaterial, Chemistry, Natural sciences

Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .

Key Points: 
  • Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .
  • According to a latest report published by PERSISTENCE MARKET RESEARCH, the global biocompatible materials market is anticipated to experience a CAGR of over 9% during the forecast period (2020 2030).
  • The synthetic polymers segment, under material type, is expected to hold significant revenue share in the biocompatible materials market.
  • In terms of regional growth, North America, Europe, and Asia Pacific are manufacturing hubs for biocompatible materials, and are anticipated to witness rapid growth in the global biocompatible materials market.

Biocompatible Materials Market to Reach US$ 347 Bn by 2030; COVID-19 Restrictions to Moderately Affect Growth Prospects in Near Term - Persistence Market Research

Retrieved on: 
Friday, January 22, 2021
Biomolecules, Acrylamides, Monomers, N-(2-Hydroxypropyl) methacrylamide, Biomaterial, Chemistry, Natural sciences

Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .

Key Points: 
  • Hence, increasing investments by companies for advanced product development that are non-toxic and non-immunogenic are also expected to create growth opportunities for the biocompatible materials market .
  • According to a latest report published by PERSISTENCE MARKET RESEARCH, the global biocompatible materials market is anticipated to experience a CAGR of over 9% during the forecast period (2020 2030).
  • The synthetic polymers segment, under material type, is expected to hold significant revenue share in the biocompatible materials market.
  • In terms of regional growth, North America, Europe, and Asia Pacific are manufacturing hubs for biocompatible materials, and are anticipated to witness rapid growth in the global biocompatible materials market.

ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 30, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Clinical medicine, Medical specialties, Immunology, Medicine, Antineoplastic drugs, Biotechnology, ImmunoGen, Antibody-drug conjugate, ImmunoGen, N-(2-Hydroxypropyl) methacrylamide

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
  • The presentation is scheduled for 10:50am ET on January 13, 2021.
  • Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGens management team for a question-and-answer session at 11:10am ET.
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs

Retrieved on: 
Tuesday, December 22, 2020
Anthracyclines, Doxorubicin, Teratogens, Drugs, N-(2-Hydroxypropyl) methacrylamide, Chemistry, Health

The patent, which expands the Companys camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions.

Key Points: 
  • The patent, which expands the Companys camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions.
  • The analogs covered in this patent have been designed to retain the potentially favorable non-cardiotoxic chemical backbone of camsirubicin and the potent broad-spectrum antitumor activity of doxorubicin; further, preclinical evidence suggests that this new family of 2-pyrrilino camsirubicin analogs could be active in doxorubicin-resistant tumor cells.
  • This may enable us to address additional cancer types beyond those possible with camsirubicin, said Andrew Mazar, PhD, Monopars Chief Scientific Officer.
  • Monopar Therapeutics is a clinical-stage biopharmaceutical companyprimarilyfocused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.

Creative Contactless Disinfection Solutions Arise in a Time of Need

Retrieved on: 
Wednesday, October 28, 2020
Bactericides, Disinfectant, Hygiene, N-(2-Hydroxypropyl) methacrylamide, Ultraviolet, Physical sciences, Chemistry, Natural sciences

In response to the pandemic, new disinfecting technology has appeared, utilizing UV light or, on a larger scale, automatic vehicle disinfections.

Key Points: 
  • In response to the pandemic, new disinfecting technology has appeared, utilizing UV light or, on a larger scale, automatic vehicle disinfections.
  • The billboards are currently located on high traffic areas particularly surrounding the Beverly Hills access areas.
  • A growing number of our clients have been waiting for more non-toxic solutions for disinfecting their immediate surroundings, and the OPTEC iWandis just great for that purpose.
  • The initial application focuses on patenting Halberd's base Covid-19 antibody as well as an entire new class of antibody conjugate.

Creative Contactless Disinfection Solutions Arise in a Time of Need

Retrieved on: 
Wednesday, October 28, 2020
Bactericides, Disinfectant, Hygiene, N-(2-Hydroxypropyl) methacrylamide, Ultraviolet, Physical sciences, Chemistry, Natural sciences

In response to the pandemic, new disinfecting technology has appeared, utilizing UV light or, on a larger scale, automatic vehicle disinfections.

Key Points: 
  • In response to the pandemic, new disinfecting technology has appeared, utilizing UV light or, on a larger scale, automatic vehicle disinfections.
  • The billboards are currently located on high traffic areas particularly surrounding the Beverly Hills access areas.
  • A growing number of our clients have been waiting for more non-toxic solutions for disinfecting their immediate surroundings, and the OPTEC iWandis just great for that purpose.
  • The initial application focuses on patenting Halberd's base Covid-19 antibody as well as an entire new class of antibody conjugate.

Visiongain publishes Colon Targeting Drug Delivery Market 2020-2030 report

Retrieved on: 
Monday, August 31, 2020
Drug delivery, Medical equipment, N-(2-Hydroxypropyl) methacrylamide

LONDON, Aug. 31, 2020 /PRNewswire/ -- The colon targeting drug delivery market is estimated to grow at a CAGR of 9.23% over the forecast period.

Key Points: 
  • LONDON, Aug. 31, 2020 /PRNewswire/ -- The colon targeting drug delivery market is estimated to grow at a CAGR of 9.23% over the forecast period.
  • The 232-page Visiongain report provides clear detailed insight into the colon targeting drug delivery market.
  • This Visiongain report includes data analysis and invaluable insight into how COVID-19 will affect your industry.
  • To request sample pages from this report please email [email protected] or refer to our website: https://www.visiongain.com/report/colon-targeting-drug-delivery-market-r...
    This report also breaks down the revenue forecast to 2030 for the global colon targeting drug delivery market by approaches & polymers type:
    Newly Developed Approaches for CDDS categorized into:

Visiongain publishes Colon Targeting Drug Delivery Market 2020-2030 report

Retrieved on: 
Monday, August 31, 2020
Drug delivery, Medical equipment, N-(2-Hydroxypropyl) methacrylamide

LONDON, Aug. 31, 2020 /PRNewswire/ -- The colon targeting drug delivery market is estimated to grow at a CAGR of 9.23% over the forecast period.

Key Points: 
  • LONDON, Aug. 31, 2020 /PRNewswire/ -- The colon targeting drug delivery market is estimated to grow at a CAGR of 9.23% over the forecast period.
  • The 232-page Visiongain report provides clear detailed insight into the colon targeting drug delivery market.
  • This Visiongain report includes data analysis and invaluable insight into how COVID-19 will affect your industry.
  • To request sample pages from this report please email [email protected] or refer to our website: https://www.visiongain.com/report/colon-targeting-drug-delivery-market-r...
    This report also breaks down the revenue forecast to 2030 for the global colon targeting drug delivery market by approaches & polymers type:
    Newly Developed Approaches for CDDS categorized into:

Tarveda Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Thursday, July 30, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Hsp90, N-(2-Hydroxypropyl) methacrylamide, Heat shock protein, Antineoplastic drugs, Chemistry, Biology

Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.

Key Points: 
  • Mr. Fromkin will also participate in a fireside chat at the BTIG Virtual Biotechnology Conference, occurring August 10-11, 2020.
  • Tarvedas Pentarin miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells.
  • Tarveda currently has two Pentarin miniature drug conjugates in clinical trials.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.